Cph Muskelterapi ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 17.3% 14.7% 12.9% 16.0%  
Credit score (0-100)  0 9 13 17 8  
Credit rating  N/A B B B B  
Credit limit (kDKK)  0.0 -0.0 -0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 140 58.4 278 281  
EBITDA  0.0 -116 2.0 -12.3 46.4  
EBIT  0.0 -116 2.0 -12.3 46.4  
Pre-tax profit (PTP)  0.0 -116.8 1.3 -12.5 42.5  
Net earnings  0.0 -91.2 1.3 -10.1 42.5  
Pre-tax profit without non-rec. items  0.0 -117 1.3 -12.5 42.5  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 -51.2 -49.9 -60.0 -17.4  
Interest-bearing liabilities  0.0 24.3 13.4 13.6 24.0  
Balance sheet total (assets)  0.0 52.9 63.3 68.8 59.4  

Net Debt  0.0 4.6 -11.5 -8.9 0.6  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 140 58.4 278 281  
Gross profit growth  0.0% 0.0% -58.3% 376.5% 1.2%  
Employees  0 0 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 53 63 69 59  
Balance sheet change%  0.0% 0.0% 19.6% 8.6% -13.6%  
Added value  0.0 -116.3 2.0 -12.3 46.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 1.0 -1.0 1.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% -83.1% 3.4% -4.4% 16.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -111.6% 2.1% -10.1% 45.2%  
ROI %  0.0% -478.5% 12.1% -90.6% 247.1%  
ROE %  0.0% -172.3% 2.3% -15.3% 66.4%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% -49.2% -44.1% -46.6% -22.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -4.0% -581.5% 72.5% 1.3%  
Gearing %  0.0% -47.4% -26.9% -22.7% -137.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 4.6% 5.0% 2.1% 20.9%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.5 0.6 0.5 0.8  
Current Ratio  0.0 0.5 0.6 0.5 0.8  
Cash and cash equivalent  0.0 19.7 24.9 22.5 23.4  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 -51.2 -49.9 -60.0 -17.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 2 -12 46  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 2 -12 46  
EBIT / employee  0 0 2 -12 46  
Net earnings / employee  0 0 1 -10 43